Dorzolamide

Dorzolamide

SCHEMBL4455530

CCN[C@@H]1C[C@@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CA2

The experimentally established mechanism targets of Dorzolamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA2 known ✓ P00918 18/20 1.00
CA1 P00915 3/20 1.00
CA12 O43570 1/20 1.00
CA3 P07451 1/20 1.00
AR P10275 1/20 1.00
CA4 P22748 1/20 1.00
CA6 P23280 1/20 1.00
CA5A P35218 1/20 1.00
CA7 P43166 1/20 1.00
CA9 Q16790 1/20 1.00
CA13 Q8N1Q1 1/20 1.00
CA14 Q9ULX7 1/20 1.00
CA5B Q9Y2D0 1/20 1.00
LMNA P02545 1/20 1.00
TSHR P16473 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dorzolamide SCHEMBL9914274 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL4525137 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL24061 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL12453422 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL12874119 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL3306381 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL12223216 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL9914275 1.00 CA2 (1.00) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL3314050 0.99 CA2 (0.98) CA2CA1CA12CA3AR
Dorzolamide SCHEMBL28388851 0.99 CA2 (0.98) CA2CA1CA12CA3AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275759-A1 PROCESS FOR PREPARING DORZOLAMIDE ZACH SYSTEM S.P.A. (IT) 2009-11-05 US claimed
US-4797413-A Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use MERCK & CO., INC. (US) 1989-01-10 US claimed
US-9481686-B2 Process for preparing enantiomerically enriched oxamides ZACH SYSTEM S.P.A. (IT) 2016-11-01 US disclosed
US-20150191485-A1 Process for Preparing Enantiomerically Enriched Oxamides F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2015-07-09 US disclosed
EP-2870162-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED OXAMIDES ZaCh System S.p.A. (IT) 2015-05-13 EP disclosed
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2014-08-21 US disclosed
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS THE HOSPITAL FOR SICK CHILDREN (CA) 2014-08-21 US disclosed
US-8748177-B2 Compositions for proliferation of cells and related methods THE HOSPITAL FOR SICK CHILDREN (CA) 2014-06-10 US disclosed
US-8748177-B2 Compositions for proliferation of cells and related methods THE HOSPITAL FOR SICK CHILDREN (CA) 2014-06-10 US disclosed
WO-2014005943-A1 PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED OXAMIDES ZACH SYSTEM S.P.A. (IT) 2014-01-09 WO disclosed
US-8183391-B2 Process for preparing dorzolamide ZACH SYSTEMS S.P.A. (IT) 2012-05-22 US disclosed
EP-1329453-B1 METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-B)-THIOPYRAN-2-SULFONAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS RAGACTIVES SL (ES) 2004-06-16 EP disclosed
US-20030220509-A1 Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates RAGACTIVES, S.L. 2003-11-27 US disclosed
EP-1329453-A1 METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-B)-THIOPYRAN-2-SULFAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS Ragactives, S.L. (ES) 2003-07-23 EP disclosed
EP-0296879-B1 SUBSTITUTED AROMATIC SULFONAMIDES AS ANTIGLAUCOMA AGENTS MERCK & CO. INC. (US) 1993-03-17 EP disclosed
US-4863922-A Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use MERCK & CO., INC. (US) 1989-09-05 US disclosed
US-4824968-A REMOVING HYDROXYL GROUP WITH SODIUM IODIDE AND DICHLORODIMETHYLSILANE IN ACETONITRILE MERCK & CO., INC. (US) 1989-04-25 US disclosed
US-4820848-A Substituted aromatic sulfonamides as antiglaucoma agents MERCK & CO., INC. (US) 1989-04-11 US disclosed
US-4797413-A Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use MERCK & CO., INC. (US) 1989-01-10 US disclosed
EP-0296879-A1 Substituted aromatic sulfonamides as antiglaucoma agents MERCK & CO. INC. (US) 1988-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191485-A1 Process for Preparing Enantiomerically Enriched Oxamides OTC, CYP11B2, QDPR CA2 162/4885CA1 1608/4885CA12 1271/4885
US-20140234271-A1 COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS MKI67, KRT18, PROX1 CA2 1728/4885CA1 2170/4885CA12 1642/4885
US-20090275759-A1 PROCESS FOR PREPARING DORZOLAMIDE SRR, DHX36, DHPS CA2 993/4885CA1 883/4885CA12 1166/4885
US-20030220509-A1 Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates CA7, CA2, CA4 CA2 2/4885CA1 24/4885CA12 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.